Determination of the molecular relationship between multiple tumors within one patient is of clinical importance

被引:58
作者
van der Sijp, JRM
van Meerbeeck, JPAM
Moat, APWM
Zondervan, PE
Sleddens, HFBM
van Geel, AN
Eggermont, AMM
Dinjens, WNM
机构
[1] Erasmus Univ, Med Ctr, Josephine Nefkens Inst, Dept Pathol, NL-3000 DR Rotterdam, Netherlands
[2] Univ Hosp Dijkzigt, Dept Surg Oncol, Dr Daniel Hoed Clin, Rotterdam, Netherlands
[3] Univ Hosp Dijkzigt, Dept Pulmonol, Rotterdam, Netherlands
[4] Univ Hosp Dijkzigt, Dept Thorac Surg, Rotterdam, Netherlands
关键词
D O I
10.1200/JCO.20.4.1105
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the molecular relationship between multiple tumors within one patient and to evaluate the impact of this knowledge on clinical management. Patients and Methods: In 25 consecutive patients with multiple tumors, proven by histology and immunohistochemistry to be identical, molecular aberrations were determined. Each patient had at least one lesion in the lung or head and neck region. Loss of heterozygosity (LOH) and p53 aberration analyses were carried out, and similar aberration profiles suggest clonality and metastasis whereas different profiles suggest independent primary tumors. Results: The molecular determinations indicated that 12 patients had a probable second primary tumor and 10 patients had a metastasis of the first lesion. in three patients, both an independent primary tumor and a metastasis were present. The molecular findings determined the course of additional treatment in all 10 patients with metastases, in all three patients with both a second primary tumor and a metastasis, and in seven of 12 patients with a second primary tumor. Conclusion: By comparing DNA alterations of multiple tumors within one patient, the relationship between the tumors can be assessed. This study shows that in 20 of 25 patients, knowledge of the nature of both lesions was essential in clinical decision making. Furthermore, after thorough analysis of the five cases where clinical decision making was not influenced, there was in retrospect no clear indication for LOH or p53 analysis. Because these molecular analyses can be performed on routine specimens, they can be applied in almost all patients. (C) 2002 by American Society of Clinical Oncology.
引用
收藏
页码:1105 / 1114
页数:10
相关论文
共 36 条
[1]  
AKMAN C, 2000, LUNG CANCER S1, V29, P216
[2]   Molecular assessment of clonality leads to the identification of a new germ line TP53 mutation associated with malignant cystosarcoma phyllodes and soft tissue sarcoma [J].
Bot, FJ ;
Sleddens, HFBM ;
Dinjens, WNM .
DIAGNOSTIC MOLECULAR PATHOLOGY, 1998, 7 (06) :295-301
[3]  
Califano J, 1999, CLIN CANCER RES, V5, P1862
[4]   Multiple primary tumours in patients with oral squamous cell carcinoma [J].
Cianfriglia, F ;
Di Gregorio, DA ;
Manieri, A .
ORAL ONCOLOGY, 1999, 35 (02) :157-163
[5]  
de Vries N, 1999, RECENT RESULTS CANC, V151, P13
[6]   Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder [J].
Friedrich, MG ;
Riethdorf, S ;
Erbersdobler, A ;
Tiemer, C ;
Schwaibold, H ;
Sölter, JK ;
Huland, E ;
Riethdorf, L ;
Conrad, S ;
Hammerer, PG ;
Huland, H .
EUROPEAN UROLOGY, 2001, 39 (02) :159-166
[7]  
Fujita T, 1999, INT J ONCOL, V15, P927
[8]  
Gallo O, 1999, INT J CANCER, V82, P180, DOI 10.1002/(SICI)1097-0215(19990719)82:2<180::AID-IJC5>3.3.CO
[9]  
2-G
[10]   DETECTION OF LOSS OF HETEROZYGOSITY AT THE HUMAN TP53 LOCUS USING A DINUCLEOTIDE REPEAT POLYMORPHISM [J].
JONES, MH ;
NAKAMURA, Y .
GENES CHROMOSOMES & CANCER, 1992, 5 (01) :89-90